scholarly journals Problems of low activity and remission in systemic lupus erythematosus

2019 ◽  
Vol 57 (2) ◽  
pp. 218-221 ◽  
Author(s):  
S. K. Soloviev ◽  
E. A. Aseeva ◽  
E. G. Zotkin ◽  
S. Yu. Kireeva ◽  
E. L. Nasonov
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Organ Damage ◽  
Systemic Lupus ◽  
Term Survival ◽  
Long Term Survival ◽  
Definition Of ◽  
Low Activity

In recent years, the long-term survival of patients with systemic lupus erythematosus (SLE) has increased to more than 90%, but there are still quite a few unresolved problems. Although the main objective of the concept of «Treatment of SLE to target» is «remission of symptoms and absence of organ damage», it was recognized that there is currently no generally accepted definition of remission in SLE. The article discusses different variants of the definition of «remission» in SLE.

Paraneoplastic Pemphigus: A Case of Long-Term Survival Associated with Systemic Lupus erythematosus and Polymyositis

Dermatology ◽  
1999 ◽  
Vol 199 (1) ◽  
pp. 63-66 ◽  
Author(s):  
J.M. Mascaró Jr. ◽  
J. Ferrando ◽  
M.T. Solé ◽  
M. Alsina ◽  
H.C. Nousari ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Term Survival ◽  
Long Term Survival ◽  
Paraneoplastic Pemphigus

scholarly journals Long-Term Survival and Death Causes of Systemic Lupus Erythematosus in China

Medicine ◽  
2015 ◽  
Vol 94 (17) ◽  
pp. e794 ◽  
Author(s):  
Ziqian Wang ◽  
Yanhong Wang ◽  
Rongrong Zhu ◽  
Xinping Tian ◽  
Dong Xu ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Term Survival ◽  
Long Term Survival ◽  
Death Causes

scholarly journals Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus

Rheumatology ◽  
2018 ◽  
Vol 57 (10) ◽  
pp. 1743-1751 ◽  
Author(s):  
Chung-Yuan Hsu ◽  
Yu-Sheng Lin ◽  
Tien-Tsai Cheng ◽  
Ya-Jhu Syu ◽  
Ming-Shyan Lin ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Term Survival ◽  
Long Term Survival

Long-term Survival of Southern Chinese Patients With Systemic Lupus Erythematosus

Medicine ◽  
2005 ◽  
Vol 84 (4) ◽  
pp. 218-224 ◽  
Author(s):  
Chi Chiu Mok ◽  
Anselm Mak ◽  
Wai Po Chu ◽  
Chi Hung To ◽  
Sik Nin Wong
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Chinese Patients ◽  
Systemic Lupus ◽  
Term Survival ◽  
Long Term Survival ◽  
Southern Chinese

History of systemic lupus erythematosus

2016 ◽  
Author(s):  
Manuel F. Ugarte-Gil ◽  
Graciela S. Alarcón
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Familial Aggregation ◽  
English Literature ◽  
Tenth Century ◽  
Immunosuppressive Drugs ◽  
Systemic Lupus ◽  
History Of ◽  
Definition Of

The first description of cutaneous ulcerations consistent with systemic lupus erythematosus (SLE) has been attributed to Hippocrates. The term lupus first appeared in English literature in the tenth century. Until the nineteenth century, however, this term was used to describe different conditions. Osler first recognized that organ involvement may occur with or without skin involvement. With the discovery of LE cells and autoantibodies, the use of lupus murine models, and the recognition of familial aggregation and the importance of genetic factors, the pathogenesis of SLE started to be unravelled and allowed the definition of classification criteria. In parallel, the discovery of cortisone, the use of immunosuppressive drugs and antimalarials, the control of hypertension, and the availability of renal replacement therapy improved the prognosis of SLE from a 4-year survival of 51% to a 5-year survival >90%. Advances in genetics and targeted therapies will lead to better intermediate and long-term outcomes.

scholarly journals Resolution of the Expert Council «The role of type I interferon inhibitor in the treatment of patients with systemic lupus erythematosus»

2021 ◽  
Vol 15 (4) ◽  
pp. 126-128
Author(s):  
A. M. Lila ◽  
S. K. Soloviev ◽  
T. V. Popkova
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Organ Damage ◽  
Immunosuppressive Drugs ◽  
Type I ◽  
Type I Ifn ◽  
Systemic Lupus ◽  
Key Points

On April 28, 2021, a meeting of the Council of Experts was held with the participation of the leading experts in the field of rheumatic diseases, approaches to the treatment of patients with systemic lupus erythematosus (SLE) were discussed. The issues of medical care for patients with SLE and their routing, key points of Russian and international clinical guidelines for the management of patients with SLE, as well as the role of interferon (IFN) type I in the pathogenesis of the disease were discussed. It is noted that the management of patients with SLE requires a multidisciplinary approach. The basis of therapy is the use of glucocorticoids (GC), immunosuppressive drugs and their combinations. But long-term use of GC in patients with SLE leads to severe complications. Early prescription of biological disease-modifying antirheumatic drugs (bDMARDs) allows to achieve the greatest effect and prevent the development of irreversible organ damage associated with SLE. Currently data from three clinical trials on the efficacy and safety of the type I IFN inhibitor anifrolumab are available. During the discussion, experts defined the clinical profile of a patient with SLE, for whom administration of bDMARD therapy is indicated. According to experts, the use of a type I IFN inhibitor in routine clinical practice can improve disease outcomes in both short and long term.

Sign in / Sign up

Export Citation Format

Share Document